Sellas Life Sciences News and Activities
Presence
Sellas Life Sciences develops cancer therapies and immunotherapy products for hospitals, oncologists, and patients. Its services focus on clinical-stage drug development for blood cancers and solid tumors.
Sellas Life Sciences products and services overview:
- Cancer therapies
- Immunotherapy products
- Drug development
- Clinical research
Revenue: ~$0 million
Employees: 20
Headquarters: Zug, Switzerland
Sellas Life Sciences is one of the...
Sellas Life Sciences is a company listed under the stock ticker SLS (CH).
Executives
View the org chart displaying its 11 main executives
Most searched biographies at Sellas Life Sciences
- Angelos Stergiou, Chief Executive Officer and Director
- Jane Wasman, Chairman of the Board
- Robert Van Nostrand, Director
Create your alert
to follow the executive moves at Sellas Life Sciences.
Healthcare
Sellas Life Sciences has 3,603 competitors including UnitedHealth Group (United States (USA)), Kaiser Permanente (United States (USA)) and HCA (United States (USA)).
Popular M&A news in Healthcare
- Custom Health is now listed under ticker CHLT. (posted on June 25 2026).
- Phreesia has acquired AccessOne (posted on June 25 2026).
- Cadence Solutions has just announced a $100 Million fundraising (posted on June 24 2026).
Popular contacts in Healthcare
News
Press releases by Sellas Life Sciences
- SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
- SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
- SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
- SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
- SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
- SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
- SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
- SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
- View more press releases Close
Social media about Sellas Life Sciences
- Sellas Life Sciences on Wikipedia, Google News & Yahoo Finance
- Sellas Life Sciences on LinkedIn, X (Twitter) & YouTube
